Dermatitis News

NEW ORLEANS — Phase 3 trial results found delgocitinib cream to significantly improve patient and clinician-reported outcomes of hand eczema, according to a presenter at the American Academy of Dermatology Annual Meeting.

NEW ORLEANS — Patients with atopic dermatitis experienced a rapid and sustained reduction in itch with topical roflumilast cream treatment, according to phase 3 study results presented at the American Academy of Dermatology Annual Meeting.

NEW ORLEANS — Although Black patients with atopic dermatitis treated with dupilumab experienced fewer adverse events than their white counterparts, the difference did not reach statistical significance, according to a poster presented here.

Results showed that Vtama cream 1% was safe, effective and well tolerated in a phase 3 study evaluating the cream in adults and children aged as young as 2 years with atopic dermatitis, Dermavant Sciences announced in a press release.

SAN ANTONIO — Training improved pediatricians’ adherence to guidelines for assessing eczema in infants before early peanut introduction, according to a presentation at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

The FDA has accepted for review the supplemental biologics license application for Dupixent for the treatment of chronic spontaneous urticaria, Regeneron Pharmaceuticals and Sanofi announced in a press release.

An immune and lipid profile on the surface of infants’ skin may predict the future development of atopic dermatitis months before the condition’s chronic onset, according to a study.

Roflumilast cream 0.15% and 0.05% demonstrated consistent efficacy across endpoints and a favorable tolerability and safety profile in the treatment of adults and adolescents with mild to moderate atopic dermatitis, according to a study.

SAN ANTONIO — Daily use of an emollient may reduce the risk for atopic dermatitis among infants with loss-of-function filaggrin mutations, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

A new drug application submitted to the FDA seeks approval of roflumilast foam 0.3% for adults and adolescents with moderate to severe seborrheic dermatitis, Arcutis Biotherapeutics announced in a press release.